177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot
- PMID: 39293463
- DOI: 10.1016/S0140-6736(24)01919-6
177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot
Conflict of interest statement
JM has served as an advisor for AstraZeneca, Amgen, Pfizer, Janssen, Amonix/Sanofi, Roche, Medendi, and Nuage Therapeutics; and has received research funding from AstraZeneca, Pfizer, and Amgen. AJZ has served as an advisor for AstraZeneca, Bayer, Exelixis, Foundation Medicine, and Pfizer; reports payments for speaking or manuscript support from Amedco, CancerNet, Hikma, Janssen-Cilag, Mckesson Specialty Health, and Pfizer; and declares grants or contracts from Merck, Pfizer, Astellas, ABX, Clarity, and Curium.
Comment on
-
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.Lancet. 2024 Sep 28;404(10459):1227-1239. doi: 10.1016/S0140-6736(24)01653-2. Epub 2024 Sep 15. Lancet. 2024. PMID: 39293462 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
